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Summary  Hepatitis  B  virus  (HBV)  infection  is  known  as  a  life-threatening  liver
infection  and  leads  to  chronic  liver  disease  if  left  untreated.  Nevertheless,  the
prevalence  of  HBV  infection  has  been  reduced  by  an  approved  vaccination  approach
using  recombinant  Hepatitis  B  surface  Antigen  (HBsAg)  and  Alum,  known  as  the  HBV
vaccine.  Alum  can  be  used  as  an  adjuvant  to  increase  HBsAg  immunogenicity  as  a
strong  Th2  stimulator.  There  is  a  vital  need  to  stimulate  Th1  immunity  by  HBsAg
Abbreviations: HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; SeNPs, selenium nanoparticles; ELISA, enzyme-linked
immunosorbent assay; PBS, phosphate buffered saline; CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma;
HEPES, 4-2-hydroxyethylpiperazine-1-2-ethanesulfonic acid; FBS, fetal bovine serum; BrdU, 10X 5-bromo-2′-deoxyuridine; PBS-BSA,
phosphate buffered saline with bovine serum albumin; PBMCs, peripheral blood mononuclear cells; PHA, phytohaemagglutinin; NK,
natural killer; TMB, tetra-methyl benzidine; SI, stimulation index; HRP, horseradish peroxidase.
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vaccination;  however,  the  present  vaccine  does  not  induce  a  prophylactic  immune
response  in  some  groups.  The  main  aim  of  the  present  study  was  to  induce  a  Th1
cytokine  pattern  and  stimulate  an  immune  response  after  HBsAg  vaccination.  Experi-
mental  mice  were  fed  selenium  nanoparticles  (SeNPs)  and  were  later  immunized  with
5  g  of  Hepatitis  B  Vaccine.  After  a  period  of  30  days,  the  experimental  animals  were
given  two  booster  doses  of  SeNPs  during  their  vaccination  course.  Group  one,  i.e.,
the  control  vaccine  group,  was  only  administered  the  HBsAg  vaccine.  The  two  treated
groups,  Groups  2  and  3,  were  daily  fed  different  doses  of  SeNPs  (100  g  and  200  g,
respectively)  via  gavage.  Group  four  was  considered  the  control  group  and  was  only
given  phosphate  buffered  saline  (PBS).  Lymphocyte  proliferation,  IFN- and  IL-4  lev-
els,  total  antibody  and  the  isotypes  of  IgG1,  IgG2a,  IgG2b,  and  IgM  were  measured  by
Enzyme  Linked  Immunosorbent  Assay  (ELISA).  The  administration  of  SeNPs  and  the  HBs
antigen  vaccine  affected  the  lymphocyte  proliferation;  moreover,  the  total  antibody
responses  also  increased  the  IFN- level  and  induced  a  Th1  response.
Conclusions:  The  present  study  proposed  that  the  administration  of  SeNPs  with  a
conventional  HBs  antigen  vaccine  induces  a  better  immune  response  with  a Th1  bias.
©  2016  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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Therefore,  in  the  present  study,  we  hypothesizedLimited.  All  rights  reserv
ackground
epatitis  B  virus  (HBV)  infection  is a  hazardous  liver
nfection.  Globally,  over  350  million  people  suf-
er from  persistent  HBV  infection.  At  least  600,000
atients die  of  hepatitis  B  virus  (HBV)-related  dis-
ases, including  Chronic  Hepatitis  B  (CHB),  Liver
irrhosis  (LC),  and  Hepatocellular  Carcinoma  (HCC)
nnually  [1].  A  signiﬁcant  reduction  in  HBV  infec-
ion prevalence  has  been  achieved  by  an  approved
accination approach  using  recombinant  Hepati-
is B surface  Antigen  (HBsAg)  [2]. However,  some
iabetic  and  hemodialysis  patients  and  12—21%
f healthy  vaccinated  adults  do  not  develop  an
dequate  response  following  the  HBsAg  vaccine
3].  It  has  been  demonstrated  that  a  Th1  immune
esponse is  related  to  the  successful  development
f humoral  immune  responses  against  HBs  anti-
en [4].  One  important  immunologic  ﬁnding  in  the
on-responder  patients  is  a  defect  in  IFN-  pro-
uction due  to  the  interference  of  the  virus  with
ytokine production,  which  ﬁnally  weakens  the
ellular  immune  response  and  results  in  disease
rogression [5], stimulation  of  cellular  immune
esponse and  the  Th1  cytokine  platform  that  is
ritical  for  the  disease  control  and  treatment.
his strategy,  known  as  therapeutic  vaccination,  is
ffective in  patients  and  viably  controls  the  dis-
ase. Although  alum  is  used  as  an  ordinary  adjuvant
n the  HBs  vaccine  formulation  for  its  induction
f a  strong  humoral  immune  response,  it  failed  to
t
w
tnduce  cellular  immune  responses  [6].  Herein,  the
tilization  of  an  immunomodulator  agent  in  paral-
el with  HBs  vaccination  may  be  useful  to  induce
oth cellular  as  well  as  humoral  immune  responses.
elenium plays  a  dominant  role  in  many  processes
uch as  immune  system  modulation,  antioxidant
nd anticarcinogenic  effects,  cancer  prevention,
nd antiviral  activities  [7].
Elemental selenium  in  the  Se0 state  is  an  insolu-
le metalloid  compound  chemically  or  biologically
roduced at  the  nanoscale.  Selenium  nanoparti-
les (SeNPs)  have  gained  attention  in  recent  years
ue to  their  excellent  biological  properties,  which
re similar  to  selenium  ions  but  in even  lower
oses and  with  less  toxicity  [8]. According  to
revious  studies,  the  administration  of  SeNPs  to
ice increased  Th1  immune  responses  and  trig-
ered cytokine  production  such  as  IFN-,  TNF-,
L-12  and  IL-2  [9]. This  immunologic  proﬁle  clearly
howed  that  selenium  possesses  the  ability  to
olarize  the  immune  system  toward  a  Th1  pat-
ern and  thereby  increase  the  efﬁcacy  of  vaccines
gainst many  viral  and  bacterial  pathogens  specif-
cally controlled  by  cellular  immune  responses.
his in  turn  authenticated  the  relationship  between
FN- release  and  successful  antibody  secretionhat the  oral  feeding  of  SeNPs  to  mice  immunized
ith HBsAg  will  result  in  IFN-  secretion  in  addition
o improving  their  humoral  immune  responses.
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Materials and methods
Selenium nanoparticles’ preparation and
characterization
A  5.2  mM  selenium  dioxide  solution  (Merck,
Germany) was  prepared  and  an  aqueous  ascorbic
acid solution  (5.2  mM)  was  slowly  added  to  the  mix-
ture with  continuous  stirring  at  300  rpm  using  a
laboratory  magnetic  stirrer.  Later,  the  mixture  was
centrifuged  and  washed  three  times  with  double-
distilled water.  The  NPs’  surface  and  elemental
composition were  studied  by  ﬁeld  emission  scan-
ning electron  microscope  (FESEM)  equipped  with
energy-dispersive  X-ray  spectroscopy  (EDS).  The
NPs were  coated  with  gold  and  mounted  on  spec-
imen  stubs.  MIRA  3  FISEM  (MIRA  3 TESCAN,  USA)
was operated  at  15  kV  to  analyze  the  samples.
Moreover, the  EDX  was  applied  by  focusing  on  a
cluster of  NPs.  The  surface  charge  of  the  nanoparti-
cles was  determined  by  Malvern  Zetasizer  (Malvern
Instruments GmbH,  Herrenberg).  A  stock  solution  of
SeNPs was  prepared  (1  mg/ml)  and  used  for  further
oral administration  in  100  and  200  l doses.
HBV vaccine and HBs Ag
Conventional  HBV  vaccine  (HBs-Ag  formulated  in
Alum adjuvant)  and  HBs-Ag  supplied  by  the  Pasteur
Institute  of  Iran  (Karaj,  Iran)  were  stored  at  4 ◦C
until use.
Experimental animals
Sixty  six-to-eight-week-old  female  inbred  BALB/c
mice were  purchased  from  the  Pasteur  Institute
of Iran  (Karaj,  Iran).  The  mice  were  housed  for  a
period of  seven  days  prior  to  the  experiments,  given
free access  to  food  and  water  and  maintained  in
standard  conditions  with  a  12  h/12  h  light/dark  and
at 18—20 ◦C.  All  experiments  were  in  accordance
with the  Animal  Care  and  Use  Protocol  of  Tehran
University, Iran.
Immunization and study planning
The  mice  were  divided  into  four  groups  with  each
group containing  ﬁfteen  mice,  and  the  oral  feeding
was carried  out  with  synthetic  SeNPs  for  a period  of
60 days.  After  30  days  of  administration,  the  mice
were immunized  subcutaneously  with  5  g  of  HBs
vaccine  in  a  total  volume  of  250  l.  After  a  period  of
14 and  28  days,  mice  were  re-administered  similar
concentrations of  booster  doses.  The  mice  in  group
one, which  was  considered  the  vaccine  control
T
s
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roup,  received  only  the  Hepatitis  B  vaccine  in  the
entioned  course.  In  group  2,  the  mice  were  fed
00 g  of  synthetic  SeNPs  for  30  days  before  and  30
ays after  immunization.  In  group  3,  the  mice  were
ed 200  g  of  synthetic  SeNPs  for  30  days  before  and
0 days  after  immunization.  In  group  4,  the  mice
ere considered  the  PBS  control  group  and  were
ed only  phosphate  buffered  saline  (PBS).
ymphocyte proliferation
wo  weeks  after  the  ﬁnal  immunization,  the  cell
uspension  was  prepared  by  dissecting  the  spleen
n cold  PBS  containing  2%  Fetal  Bovine  Serum  (FBS)
nder aseptic  conditions.  Red  blood  cells  were  lysed
y the  addition  of  5 ml  lysis  buffer  on  cell  pel-
ets. A single-cell  suspension  was  prepared  and
djusted  to  3  ×  106 cells/ml  in  RPMI-1640  (Gibco,
ermany). Next,  the  suspension  was  supplemented
ith 10%  FBS,  4  mM  L-glutamine,  25  mM  4-
-Hydroxyethlypiperazine-1-2-Ethanesulfonic  Acid
HEPES), 0.1  mM  non-essential  amino  acid,  1  mM
odium pyruvate,  50  M  2ME,  100  g/ml  strepto-
ycin and  100  IU/ml  penicillin.  Afterwards,  100  l
f a suspension  of  3 ×  105 cells  was  dispensed  in
6-well culture  plates  (Nunc,  Denmark)  and  stim-
lated with  5 g/ml  of  HBs-Ag  as  recall  antigen.
hytohemagglutinin-A  (5  g/ml;  Gibco,  Darmstadt,
ermany) was  used  as  the  positive  control,  and  the
n-stimulated  wells  were  used  as  negative  controls.
ll of  the  experiments  were  repeated  in  tripli-
ate. After  72  h  of  incubation  at  37 ◦C  in  a  5%
O2 humid  incubator,  the  cells  were  pulsed  with
0 l  of  10X  5-Bromo-2′-deoxyuridine(BrdU)  (Roche,
ermany)  per  well,  and  culture  incubation  contin-
ed for  another  24  h.  At  that  time,  the  plates  were
entrifuged  at  300  ×  g  for  10  min,  and  the  culture
edium was  removed  and  dried  at  60 ◦C.  Later,
y the  addition  of  200  l  of  ﬁxation/denaturation
uffer,  the  cells  were  permeabilized,  and  100  l  of
nti-BrdU  antibody  was  added  to  each  well.  The
lates were  washed  four  times  with  PBS  buffer,  and
etra-Methyl  Benzidine  (TMB)  solution  was  added  to
ach well.  The  reaction  was  continued  for  10  min
nd ﬁnally  stopped  by  adding  100  l  of  2N  H2SO4.
he absorbance  was  measured  using  a  synergy-4
late reader  at  450/630  nm.  Finally,  the  Stimulation
ndex (SI)  of  the  experimental  mice  was  calculated
sing: (OD  of  stimulated  wells-Blank)/(OD  of  un-
timulated  wells-Blank).
uantitative IL-4 and IFN- ELISAwo  weeks  after  the  last  immunization,  3  ×  106
pleen  cells  per  milliliter  were  re-suspended  in
omplete  RPMI  1640,  placed  in  each  well  of  a
E 105
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Figure  1  In  upper  illustration,  the  image  shows  that  the
size  of  fabricated  SeNPs  is  below  100  nm.  The  lower  illus-
tration  shows  the  EDS  spectrum  of  the  SeNPs,  conﬁrming
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Cffect  of  SeNPs  on  Hepatitis  B  vaccination  
4-well  plate  and  stimulated  with  5 g/ml  of  HBsAg
or 72  h  at  37 ◦C  in  5%  CO2.  The  supernatants  were
hen collected  and  assessed  for  IFN-  and  IL-4
ytokines using  a  commercial  ELISA  Kit  (Quantikine,
&D Systems,  US)  according  to  the  manufacturer’s
anual.
LISA of speciﬁc total antibodies and IgG1,
gG2a, IgG2b and IgM isotypes
he  speciﬁc  total  antibodies  were  evaluated  using
n optimized  indirect  ELISA  method.  Brieﬂy,  100  l
f HBsAg  (5  g/ml)  in  PBS  was  coated  in  96-well
LISA Maxisorp  plates  (Nunc,  Naperville,  IL)  fol-
owed by  an  overnight  incubation  at  4 ◦C.  The  wells
ere  washed  3  times  with  PBS  containing  0.05%
ween 20  (washing  buffer)  and  blocked  for  1  hr
t 37 ◦C with  5%  skim  milk  in  PBS  buffer  (block-
ng buffer).  Serial  dilutions  of  sera  from  1/100  to
/12,800  were  prepared  in  1%  PBS-BSA.  After  wash-
ng the  wells,  100  l  of  each  dilution  was  added  to
ach well  in  triplicate  and  incubated  at  37 ◦C  for
 h.  Then,  the  wells  were  washed  ﬁve  times  with
ashing  buffer  and  incubated  for  2  h  at  37 ◦C.  After
he incubation,  the  wells  were  washed  ﬁve  times
ith washing  buffer  and  100  l of  the  1/10,000
ilution of  anti-mouse  conjugated  to  horseradish
eroxidase Horseradish  Peroxidase  (HRP)  (Sigma)  in
hosphate Buffered  Saline  with  1%  Bovine  Serum
lbumin (PBS-BSA)  was  added  and  incubated  for  2  h
t 37 ◦C.  Later,  the  wells  were  washed  ﬁve  times
ith washing  buffer,  100  l of  TMB  substrate  was
dded, and  the  plates  were  incubated  for  30  min  in
he dark.  The  reaction  was  stopped  using  100  l  of
N H2SO4,  and  the  color  density  was  measured  at
450/630 nm  with  an  ELISA  plate  reader.  To  detect
he speciﬁc  IgG1,  IgG2a,  IgG2b  and  IgM  subclasses,
oat anti-mouse  IgG1,  IgG2a,  IgG2b  and  IgM  sec-
ndary  antibodies  (Sigma)  were  used.
tatistical analysis
NOVA  tests  were  used  to  compare  the  statisti-
al signiﬁcance  among  the  experimental  groups.
alues  of  P  <  0.05  were  considered  to  represent
tatistically signiﬁcant  differences.  The  results  are
resented as  the  mean  ±  S.D.
esultsreparation and characterization of Se NPs
he  size  and  shape  of  the  fabricated  Se  NPs
ere conﬁrmed  by  FESEM.  An  FESEM  image  of  the
I
t
S
nhe  presence  of  Se  atoms  and  the  SeNPs’  existence.
dditional  peaks  of  copper  and  carbon  elements  are
ttributed  to  the  grid  used  for  FESEM  imaging.
repared  SeNPs  is  shown  in  the  upper  illustration
n Fig.  1. The  FESEM  image  shows  that  particle
ize range  is  below  100  nm  with  an  average  size
f approximately  60  nm.  The  surface  charge  of  the
ynthesized  Se  NPs  was  −23.8  as  determined  by
alvern Zetasizer.
roliferation assay
o  assess  the  lymphocyte  proliferative  response,
plenocytes were  re-stimulated  in  vitro  with
 g/ml  of  HBsAg  for  72  h,  and  the  proliferation
ssay was  performed  using  the  BrdU  method.  In
omparison  to  the  PBS  and  vaccine  control  groups,
 signiﬁcant  increase  in  the  stimulation  index  of
he lymphocytes  was  observed  in  the  mice  that
eceived 200  g  of  synthetic  SeNPs  (P  ≤  0.05).  The
dministration  of  100  g SeNPs  had  some  effect
n lymphocyte  proliferation,  but  this  change  was
ot considerable  in  contrast  to  the  other  groups
Fig.  2).
ytokine assay in spleen cell cultureFN-  and  IL-4  were  measured  using  a quantita-
ive ELISA  method.  The  administration  of  synthetic
eNPs  at  doses  of  100  g and  200  g  caused  immu-
ization in  the  mice  and  at  a dose  of  5  g  of
106  M.  Mahdavi  et  al.
Figure  2  Lymphocyte  proliferation  responses  accord-
ing  to  the  stimulation  index.  Two  weeks  after  the  ﬁnal
immunization,  the  spleens  of  mice  were  removed  and
after  lymphocyte  preparation,  re-stimulated  in  vitro  with
5  g/ml  of  HBs  Ag  for  3  days  and  proliferation  was  eval-
Figure  3  Cytokine  production  by  splenocytes  of  experi-
mental  groups.  Two  weeks  after  the  ﬁnal  booster,  spleen
cells  were  cultured  and  stimulated  with  5  g  of  HBs  Ag.
Then,  the  quantities  of  IFN- (A)  and  IL-4  (B)  in  the
experimental  mice  were  evaluated  by  an  ELISA  method.
The  results  for  IL-4  and  IFN- (C)  are  presented  as  the
m *
a
r
h
tuated  with  the  standard  BrdU  method.  The  results  are
shown  as  the  mean  ±  SD  of  the  experimental  groups
(n  =  15) *(P  ≤  0.05).
HBsAg  vaccine  the  IFN-  secretion  was  signiﬁcantly
increased in  comparison  with  the  PBS  and  vaccine
control groups  (P  <  0.01).  The  amount  of  IL-4  level
was the  same  in  all  of  the  groups,  but  the  ratio  of
IFN- to  IL-4  was  higher  in  the  groups  that  received
100 and  200  g  doses  of  SeNPs  (Fig.  3).  The  result
demonstrates  the  potential  of  the  administration  of
synthetic SeNPs  to  viably  shift  the  immune  response
toward  the  Th1  type.
Humoral immune response and isotyping
To  obtain  speciﬁc  humoral  immune  responses
with an  optimized  indirect  ELISA  method,  ini-
tially 8 serial  dilutions  from  all  sera  (collected  2
weeks after  the  last  immunization)  were  prepared
(1/100—1/12,800),  and  then  the  total  antibodies
were evaluated.  The  results  showed  an  increase  in
the level  of  total  antibody  in  the  serum  of  the  mice
that received  100  and  200  g  doses  of  synthetic
SeNPs plus  HBs  antigen  vaccine  in  comparison  to  the
PBS and  vaccine  control  groups  (P  ≤  0.05)  (Fig.  4).
The results  of  the  antibody  isotype  measurement
showed that  the  IgM  level  rose  signiﬁcantly  in  mice
that received  100  g  SeNPs  in  comparison  to  the
vaccine and  PBS  control  groups  (P  ≤  0.05).  Mean-
while, the  levels  of  IgG1  and  IgG2b  antibody  in  the
100 and  200  doses  of  SeNPs  were  signiﬁcantly  higher
in comparison  to  the  PBS  control  group  (Fig.  5).Discussion
Vaccination  against  Hepatitis  B  infection  is  the  only
assured option  to  prevent  the  spread  of  this  disease,
t
i
i
mean  ±  SD  of  each  group  (n  =  15) (P  <  0.01).
nd  the  success  of  the  vaccination  approach  using
ecombinant  HBsAg  was  conﬁrmed  by  the  global
ealth initiative  to  minimize  the  prevalence  of
his infection  [2].  However,  non-responsiveness  to
he vaccination  has  been  widely  described  in  some
ndividuals,  such  as  hemodialysis  patients,  diabetic
ndividuals  and  the  neonates  of  hepatitis  B carrier
others.
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Figure  4  Total  IgG  antibody  in  the  experimental  groups.  Two  weeks  after  the  ﬁnal  immunization,  the  sera  of  the
e level
T D  (n
i
v
t
a
l
t
i
v
w
p
p
w
r
p
B
t
c
c
F
c
mxperimental  mice  were  collected  and  the  total  antibody  
he  data  from  each  group  are  presented  as  the  mean  ±  S
Several  studies  have  been  previously  designed  to
ncrease  vaccine  efﬁcacy,  especially  by  altering  the
accine composition  and  its  delivery  routes  [10]. In
he present  study,  the  oral  administration  of  SeNPs
s a  supplement  during  the  vaccination  schedule
ed to  an  increase  in  the  level  of  IFN-  and  its  ratio
o IL-4  (Fig.  3C).  The  importance  of  IFN-  in  the
mmune  response  against  Hepatitis  B  has  been  pre-
iously reported.  Meanwhile,  in  another  study,  it
as revealed  that  the  IFN-  content  produced  by
eripheral  blood  mononuclear  cells  (PBMCs)  after
hytohemagglutinin  (PHA)  and  HBsAg  stimulation
p
m
r
r
igure  5  Speciﬁc  IgM,  IgG1  and  IgG2a  isotypes  in  the  immu
ollected  two  weeks  after  the  ﬁnal  booster  and  the  speciﬁc  I
entioned  in  method  section.  The  results  are  presented  as  th was  evaluated  with  an  optimized  indirect  ELISA  method.
 =  15)  (P  ≤  0.05).
as  lower  in  non-responders  in  comparison  with
esponders  [11].
IFN-  is  known  as  a  Th1  network  cytokine  and
lays a  key  role  in  promoting  the  T  cell  response.
oth human  and  animal  studies  have  demonstrated
hat induction  of  T  cell  responses  is  critical  for  the
ontrol of  many  viral  infections  [12]. A  robust  T
ell immune  response  is also  promoted  at  the  acute
hase of  hepatitis  B  infection.  IFN-  has  a funda-
ental role  in  inducing  the  natural  killer  (NK)  cell
esponse,  also  known  as  the  ﬁrst  line  of  immune
esponse against  cancer  and  viral  infection.
nized  groups.  The  sera  of  the  experimental  mice  were
gM,  IgG1  and  IgG2a  were  evaluated  by  indirect  ELISA  as
e  mean  ±  SD  of  each  group  (n  =  15)  (P  =  0.003).
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We  have  previously  demonstrated  that  admin-
istration of  biogenic  SeNPs  leads  to  a  Th1-type
immune response.  In  this  study,  the  synthetic  form
of SeNPs  caused  the  same  results  for  the  induc-
tion of  cytokine  production  [9].  In  the  biogenic
form of  SeNPs,  the  surface  of  the  nanoparticles  may
be changed  due  to  residues  from  bacterial  cyto-
plasm  components  like  DNA  or  lipoproteins,  and
these elements  probably  are  involved  in  triggering
the immune  response.  Synthetic  SeNPs  reduced  by
ascorbic acid  at  the  nanoparticle  surface  did  not
have the  same  residual  elements.  The  results  of
the present  research  conﬁrmed  that  the  orches-
tration of  the  immune  cells  is  only  due  to  the
incorporation of  SeNPs.  Meanwhile,  considering  the
results of  the  BrdU  test  in  the  current  work,  our
hypothesis was  conﬁrmed,  which  was  that  synthetic
SeNPs  had  the  ability  to  stimulate  the  immune  cells
in both  proliferation  as  well  as  the  production  of
cytokines.  Cytokines  play  a  major  role  in  the  reg-
ulation,  differentiation  and  maturation  of  T and
B lymphocytes.  Despite  the  obtained  IL4  measure-
ments in  the  present  study  exhibiting  no  differences
between the  treatment  and  control  groups,  it  was
observed  that  the  total  antibody  responses  were
elevated  in  mice  that  received  both  100  and  200  g
of SeNPs  in  comparison  to  the  vaccine  and  PBS
control groups.  Meanwhile  the  ratio  of  IFN-  to  IL-
4 as  an  important  index  of  Th1/Th2  response  in
the present  work  showed  the  priority  of  the  IFN-
response  among  the  treated  mice  in  comparison  to
the controls.  Thus,  the  results  revealed  the  capac-
ity of  the  SeNPs  to  potentiate  not  only  the  humoral
branch (B  cells)  but  also  the  cellular  branch  (T cells)
of the  immune  system.
However,  the  antibody  isotype  results  indicated
that only  the  IgM  isotype  was  signiﬁcantly  raised
in the  mice  administered  100  g doses  of  SeNPs
compared to  the  control  vaccine.  Surprisingly,  the
elevation  of  cytokines  and  total  antibodies  was
slightly  higher  at  the  100  g  dose  compared  to  the
200 g  dose  of  SeNPs.  This  difference  signiﬁed  the
necessity  to  carry  out  a  detailed  investigation  of  the
dose response  relationship  of  synthetic  SeNPs.  It  is
important to  mention  here  that  several  researchers
have proposed  that  antibody  isotype  and  cytokine
proﬁles do  not  always  match  [13—15].  Therefore,
the differences  among  the  IgG  1,  IgG2a  and  IgG2b
levels in  the  SeNP-administered  mice  in  comparison
to the  control  vaccine  as  observed  in  the  present
study failed  to  increase  the  IFN-  level.  Moreover,
as far  as  a  signiﬁcant  rise  in  the  IgM  level  due
to the  SeNP  administration  in  comparison  to  the
control vaccine  was  concerned,  it  may  be  hypothe-
sized that  for  antibody  class  switching,  in  addition
to the  elevation  of  IgG  classes  of  antibody  that
i
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re  proportionally  related  to  the  IFN-  level,  an
ncreased  time  period,  i.e.,  over  15  days  or  more,
s required.
The  mechanism  underlying  the  non-
esponsiveness  to  hepatitis  B  surface  antigen
HBs) in  humans  is largely  unexplained,  although
vidence has  shown  that  different  HLA-DR  alleles
re associated  with  speciﬁc  low  responsiveness  in
ifferent ethnic  populations  [16].
Regardless  of  the  precise  reason  for  the
on-responsiveness,  any  approach  to  successfully
mprove the  immune  response  after  vaccination
gainst hepatitis  B  infection  seems  worthy  for  the
ealth surveillance  system  of  any  nation.
onclusion
he  results  of  the  present  research  show  that,
ecause SeNPs  are  a new  adjuvant  in  their  infancy
tage, they  may  be  a  good  candidate  not  only  for
ore speciﬁc  studies  in  the  aforementioned  con-
ext but  also  to  design  a new  preventive  strategy
ith different  administration  routes  for  HBV  vac-
ine studies.
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